News | November 15, 2023
JB Pharma Q2 FY24 PAT up 36% to Rs. 151 Cr
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Reports revenue growth of 9% to INR 882 crores in Q2 FY24
Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
Yesafili, received marketing authorization approval from the European Commission for the European Union
European operations' revenue grew 58.4% to Rs 599.7 crore
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
he company posted total income during Q2 FY24 at Rs. 12.86 crore
US business grew by +12.8% YoY
General Medicine grows 5% and Vaccines 10% led by Shingrix
Subscribe To Our Newsletter & Stay Updated
